Dr. Rajamannan Sends Over to the Illinois Department of Public Health Safety Concerns in Chicago Regarding FDA's Affidavit as Published in the Daily Northwestern in 2019

Press Release (ePRNews.com) - CHICAGO - Jan 24, 2020 - Most Sacred Heart of Jesus Cardiology and Valvular Institute Medical Director Dr. Nalini Rajamannan has requested the Mayor’s office to send the FDA Affidavit outlining Illinois and Minnesota patient testimonies to the Illinois and Chicago Department of Health’s Dr. Jennifer Layden and Dr. Allison Arwady.

The FDA Commissioner, Dr. Hahn, the Illinois and Minnesota Attorney General’s offices and the Chicago Mayor’s office are reviewing the Minneapolis FDA affidavits regarding patients’ rights under HHS Federal Codes for human subject research. The FDA is led by the Commissioner of Food and Drugs, appointed by President Trump with the advice and consent of the United States Senate.

The Illinois Department of Public Health now has newly discovered evidence of delays by the FDA to inform Chicagoans and U.S. citizens of a new health concern related to the testing of the non-exempt heart device.

The events follow recent reporting by Kaiser Health News that the FDA has lifted their exemption laws.​​ Dr. Nalini Rajamannan, a specialist for patients with valvular heart disease in Most Sacred Heart of Jesus Cardiology, confirms FDA statements after a decade of requesting answers from the FDA from her location in Downtown Sheboygan. Dr. Rajamannan revealed the confirmation FDA letter to Congressman Glenn Grothman that the Food and Drug Deputy Commissioner on policy for the FDA will not inform the patients regarding the status of a heart device implanted in 667 patients across the United States of America.

Former Board of Trustee for the University and now Governor of Illinois, Governor Pritzker, also received the FDA affidavit after years of delays by the FDA in reporting to the patients. The surgical placement for these devices began in 2006. In 2007, the device manufacturer confirmed the “exempt status” in a two-line email to the hospital. The saga related to the heart device is outlined by Dr. Elisabeth Rosenthal’s new book “An American Sickness“, which highlights the issues related to exempt medical devices in the chapter, “How to get into a Patient’s Heart? Follow the Money.” The chapter outlines the events summarized by eye-witness Dr. Nalini M. Rajamannan in the series “The Myxo Files a XXIV: A Tale of Three Rings“, as published by Kindle Publishing on Amazon.com. Dr. Rajamannan reviewed the FDA letter to the Senate Finance Committee’s Chairman Grassley after several years of investigations, classifying the device as not exempt from reporting the device to the FDA, and that the device manufacturer needs to submit a new approval application. (See Linked PDF of the FDA Congressional Letter.)

Summation points from the recent press conference at the Institute after a decade of FDA investigations:

1) FDA report to Senate Finance Committee confirms the Myxo ETlogix Device is not exempt and needed an approval from the FDA.

2) FDA letter to Senator Lugar confirms 667+ patients received the non-exempt device which needed an approval.

3) FDA report to the House Committee on Government Oversight confirms that the FDA does not plan to inform the patients.

4) Congressman Grothman is still waiting for a response as to why the FDA is not planning to inform the patients.

5) HHS Inspector General Daniel Levinson is not planning to inform the patients of the non-exempt status of the heart device after requests for information by Senator Ron Johnson.

6) Dr. Rajamannan Presented documents and affidavit to Senator Amy Klobuchar‘s staff in Minneapolis. Senator Klobuchar has met with Dr. Rajamannan since 2014 in Washington D.C., after the Senate Judiciary Committee began their investigation.

7) Dr. Rajamannan awaiting response by the FDA to inform the patients of the design control study under 21CFR810.30, as reviewed by the FDA Minneapolis office.

8) The goal is to obtain critical safety information to inform the patients and doctors across the country to learn about the non-exempt, non-registered heart device placed in their hearts between 2006-2007.

The information will help the 667+ patients to finally get answers about whether medical devices placed in their bodies are tested and safe, as the Food and Drug Administration begins to allow access to volumes of previously shielded data from consumers as written to then-Senator Richard Lugar (IN) and Congressman Glenn Grothman (WI). The Senate Finance committee is involved in these investigations on behalf of Medicare and Medicaid because government dollars fund the use of medical devices in patients’ health. 

More importantly, the findings published in the Daily Northwestern in 2019 will help patients know more about medical devices implanted into their bodies.

Dr. Nalini Rajamannan is a heart valve expert in the field of cardiovascular medicine. She earned her undergraduate science pre-professional degree from the University of Notre Dame, her Medical Doctorate from Mayo Medical School and her post-graduate training in Internal Medicine and Cardiology at the Mayo Clinic and Research Fellowship on the NIH training Grant. She also worked at the Mayo Clinic as a staff consultant in Internal Medicine and an Associate Professor of Medicine at Northwestern University and the Lakeside and Westside VA. Currently, she practices consultative valvular medicine and Osteocardiology at Most Sacred Heart of Jesus Cardiology and Valvular Institute, WI.

Press Contact
Oscar Delgado
​​Press Officer for Most Sacred Heart of Jesus Cardiology and Valvular Institute
Former NBC Bureau Chief Latin America

Source : Most Sacred Heart of Jesus Cardiology and Valvular Institute Follow on Google News
CATEGORIES : Healthcare


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.